Sign in
Taking people in United StatesPhase 1/2

Tests investigational drug CP-383 in adults with advanced solid tumors

Tests CP-383 in adults with advanced cancers such as lung and colorectal cancer.

Key facts

Who runs it
Tasca Therapeutics
Where
Cleveland, Dallas, Denver, Fairfax, Grand Rapids, Huntersville, Maumee, Omaha, Orlando, Philadelphia, San Antonio, St Louis, and West Valley City, United StatesSee the 13 sites
Trial code
Registry title
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Status
Recruiting
Phase
Phase 1/2
People taking part
150 people, planned
Started
27 Aug 2025
Expected to end
Feb 2029
Type of study
Interventional, 10 groups
Treatments tested
  • CP-383
Record updated
18 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic solid tumors that cannot be treated with standard therapy. Participants take CP-383 by mouth every day.

Age
18 years and older
Sex
Men and women
Disease stage
Locally advanced, recurrent or metastatic cancer that cannot be cured. Part 1: any solid tumor except brain cancer, or colorectal, small cell lung, head and neck, non-small cell lung, pancreatic or bladder cancer. Part 2: colorectal, small cell lung or head and neck cancer, or selected solid tumors except brain cancer.
Earlier treatment
People must not be able to take standard cancer therapy, or it did not help, or it was too toxic. Certain anti-cancer or other drugs within a set time before the study drug are not allowed.
Biomarker or test result
Some cancers need a specific gene mutation in the tumor. A tumor sample must be available, or the person must be willing to have a biopsy.

Main reasons for not taking part

  • Cannot swallow pills
  • Active tumor in the brain
  • Known HIV, HCV or HBV, unless controlled with an undetectable viral load
  • Clinically significant liver, heart or gastrointestinal disease
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Measurable or non measurable cancer that the research can assess for changes
  • Not eligible or able to take existing standard therapies for cancer
  • Availability of a part of a tumor for laboratory testing or willing to have a safe biopsy taken from a tumor
  • Diagnosed with locally advanced, recurrent or metastatic incurable disease
  • Part 1: any solid tumor (with the exception of brain cancer) that has progressed, standard therapy is no longer or has not helped the cancer, or is too toxic and for whom a clinical trial is an option for continued treatment
  • Part 1: specific advanced, metastatic tumor types will also be enrolled: colorectal cancer, small cell lung cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer - some of these will have a specific gene mutation in the cancer
  • Part 1: selected solid tumor cancer types (with the exception of brain cancers) that have a specific gene mutation in the cancer
  • Part 2: specific advanced, metastatic tumor types will also be enrolled: colorectal cancer, small cell lung cancer, head and neck cancer - some of these will have a specific gene mutation in the cancer; _ Part 2: selected solid tumor cancer types (with the exception of brain cancers) that have a specific gene mutation in the cancer
  • Adequate blood and urine lab tests
  • Women and men of childbearing potential with adequate contraception
  • Provides written informed consent
  • Willing to comply with the requirements of the protocol

Who cannot take part

  • Known history of HIV, HCV, HBV unless cured, controlled with undetectable viral load
  • Clinically significant liver disease
  • Significant gastrointestinal diseases
  • History of other cancer within past 5 years with certain exceptions for cancers that are likely cured
  • Significant cardiac disease
  • Other diseases that are not well controlled that could make taking the drug unsafe
  • Exposure to certain anti-cancer or other drugs within a certain period before the start of study drug
  • Inability to swallow pills
  • Active tumor in the brain
  • pregnant or lactating females

Where in United States

  • Cleveland ClinicCleveland, United StatesContact: Taussig ResearchTaking people
  • NEXT Oncology - DallasDallas, United StatesContact: Mofopefoluwa AkinwaleTaking people
  • Sarah Cannon Research Institute at HealthONEDenver, United StatesContact: HealthOne DenverTaking people
  • NEXT VirginiaFairfax, United StatesContact: Maybelle De La RosaTaking people
  • START | MidwestGrand Rapids, United StatesContact: Colleen ArmstrongTaking people
  • Carolina Biooncology InstituteHuntersville, United StatesContact: Hannah WallTaking people
  • Taylor Cancer Research CenterMaumee, United StatesContact: Stephanie Ambrose, RN, BSN, CCRCTaking people
  • Nebraska Cancer SpecialistsOmaha, United StatesContact: Ashley ServaisTaking people
  • Florida Cancer Specialists - Lake NonaOrlando, United StatesContact: Elizabeth GilmoreTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Roger Cohen, MDTaking people
  • START | San AntonioSan Antonio, United StatesContact: Isabel JimenezTaking people
  • Washington UniversitySt Louis, United StatesContact: Sara MitchumTaking people
  • START Mountain RegionWest Valley City, United StatesContact: Marie AsayTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are:

Read full original descriptionShow less

* Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further. Researchers will also see if certain cancers that have gene mutations respond better to CP-383

Participants will:

* Take CP-383 every day by mouth until the researcher learns whether CP-383 is helping slow or reduce the cancer growth * Visit the clinic weekly for the first 6 weeks for checkups and tests * Visit the clinic every 3 weeks thereafter for checkups and tests

The 10 groups in the trial

  • Dose Level 1Treatment being tested

    CP-383, single daily oral capsule, 0.8 mg

    Treatment: CP-383

  • Dose Level 2Treatment being tested

    CP-383, single daily oral capsule, 1.6 mg

    Treatment: CP-383

  • Dose Level 3Treatment being tested

    CP-383, single daily oral capsule, 3.0 mg

    Treatment: CP-383

  • Dose Level 4Treatment being tested

    CP-383, single daily oral capsule, 5.0 mg

    Treatment: CP-383

  • Dose Level 5Treatment being tested

    CP-383, single daily oral capsule, 8.0 mg

    Treatment: CP-383

  • Dose Level 6Treatment being tested

    CP-383, single daily oral capsule, 12 mg

    Treatment: CP-383

  • Expansion Arm 1Treatment being tested

    Expansion in selected tumor type at recommended Phase 2 Dose of CP-383

    Treatment: CP-383

  • Expansion Arm 2Treatment being tested

    Expansion in selected tumor type at recommended Phase 2 Dose of CP-383

    Treatment: CP-383

  • Expansion Arm 3Treatment being tested

    Expansion in selected tumor type at recommended Phase 2 Dose of CP-383

    Treatment: CP-383

  • Expansion Arm 4Treatment being tested

    Expansion in selected tumor type at recommended Phase 2 Dose of CP-383

    Treatment: CP-383

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors
Plain-language title
Tests investigational drug CP-383 in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 February 2026